株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

白斑:パイプライン製品の分析

Vitiligo - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 213131
出版日 ページ情報 英文 57 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
白斑:パイプライン製品の分析 Vitiligo - Pipeline Review, H2 2016
出版日: 2016年10月26日 ページ情報: 英文 57 Pages
概要

白斑とは、皮膚からメラニン色素(皮膚・髪・目の色を決定づける色素)が失われるという疾患です。主な症状として、若白髪(少年・青年期に、頭髪・眉毛・まつげ・髭が白色・灰色になること)や、口腔内部の組織の脱色、網膜の脱色・変色などが挙げられます。主な治療法には、コルチコステロイド療法や免疫調整剤、外科手術などがあります。

当レポートでは、世界各国での白斑治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

白斑の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

白斑:企業で開発中の治療薬

白斑:大学/機関で研究中の治療薬

白斑:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

白斑:企業で開発中の製品

白斑:大学/機関で研究中の製品

白斑の治療薬開発に従事している企業

  • Ache Laboratorios Farmaceuticos S/A
  • Biocon Limited
  • Bristol-Myers Squibb Company
  • Clinuvel Pharmaceuticals Limited
  • Sun Pharma Advanced Research Company Ltd.

白斑:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

白斑:最近のパイプライン動向

白斑:休止中のプロジェクト

白斑:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8592IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vitiligo - Pipeline Review, H2 2016, provides an overview of the Vitiligo (Dermatology) pipeline landscape.

Vitiligo is a condition in which skin loses melanin, the pigment that determines the color of skin, hair and eyes. Symptoms include premature whitening or graying of the hair on scalp, eyelashes, eyebrows or beard, loss of color in the tissues that line the inside of mouth and loss of or change in color of the inner layer of eye. Treatment includes corticosteroid therapy, immunomodulators and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vitiligo - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Vitiligo (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vitiligo (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Vitiligo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 2 respectively for Vitiligo.

Vitiligo (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vitiligo (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Vitiligo (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vitiligo (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vitiligo (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vitiligo (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vitiligo (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vitiligo (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Vitiligo Overview
  • Therapeutics Development
    • Pipeline Products for Vitiligo - Overview
  • Vitiligo - Therapeutics under Development by Companies
  • Vitiligo - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Vitiligo - Products under Development by Companies
  • Vitiligo - Companies Involved in Therapeutics Development
    • Ache Laboratorios Farmaceuticos S/A
    • Biocon Limited
    • Bristol-Myers Squibb Company
    • Clinuvel Pharmaceuticals Limited
  • Vitiligo - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • abatacept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACH-24 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • afamelanotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • itolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VLRX-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Vitiligo - Dormant Projects
  • Vitiligo - Product Development Milestones
    • Featured News & Press Releases
      • Dec 03, 2015: Positive preliminary results in Singaporean vitiligo study
      • Dec 03, 2015: Update on North American vitiligo program for SCENESSE
      • May 05, 2015: Clinuvel announces innovative melanocortin for new indications
      • Mar 20, 2015: SCENESSE vitiligo data presented at world's largest dermatology conference
      • Sep 19, 2014: SCENESSE vitiligo study results published in JAMA Dermatology
      • May 06, 2014: Clinuvel's Phase II vitiligo study commences in Singapore
      • Mar 20, 2014: SCENESSE data to feature at American Academy of Dermatology
      • Nov 04, 2013: Clinuvel to start a Phase II vitiligo study in Singapore
      • Sep 02, 2013: Five month study follow up shows SCENESSE combination treatment provided stable repigmentation in vitiligo patients
      • Mar 01, 2013: SCENESSE data to be presented at American Academy of Dermatology, San Gallicano Rare Disease conference
      • Dec 19, 2012: Clinuvel Pharma Announces Results From Phase IIa Pilot Study Of Scenesse In Vitiligo
      • Oct 16, 2012: Observations from Clinuvels US vitiligo study published
      • Mar 15, 2012: Observations from Clinuvels vitiligo and EPP programs being presented at the
      • Mar 02, 2011: Clinuvel Announces FDA Approval For Vitiligo Drug Trial
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Vitiligo, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Vitiligo - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016
  • Vitiligo - Pipeline by Biocon Limited, H2 2016
  • Vitiligo - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Vitiligo - Pipeline by Clinuvel Pharmaceuticals Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Vitiligo - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Vitiligo, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top